Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in Advanced HCC
NCT05653427Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in hepatocellular carcinoma (HCC), sponsored by Janssen Pharmaceutical. Started Dec 2022; status: terminated.
02
Drugs
amivantamab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05653427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653427.